BALA CYNWYD, Pa., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Paya Holdings Inc. (Nasdaq – PAYA)
Under the terms of the agreement, Paya will be acquired by Nuvei Corporation (Nasdaq - NVEI) (“Nuvei”). Paya stockholders will receive $9.75 per share in an all-cash transaction valued at approximately $1.3 billion. The investigation concerns whether the Paya Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Nuvei is paying too little for the Company.
Additional information can be found at https://www.brodskysmith.com/cases/paya-holdings-inc-nasdaq-paya/.
CinCor Pharma, Inc. (Nasdaq – CINC)
Under the terms of the agreement, CinCor will be acquired by AstraZeneca PLC (“AstraZeneca”) (Nasdaq – AZN). CinCor stockholders will receive $26.00 per share at closing plus a non-tradable contingent value right of $10.00 per share in cash payable upon a specified regulatory submission of a baxdrostat product. The investigation concerns whether the CinCor Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether AstraZeneca is paying too little for the Company.
Additional information can be found at https://www.brodskysmith.com/cases/cincor-pharma-inc-nasdaq-cinc/.
Albireo (Nasdaq – ALBO)
Under the terms of the agreement, Albireo will be acquired by Ipsen for $42.00 per share in cash at the closing of the transaction, for an initial estimated aggregate consideration of $952 million plus one contingent value right (CVR) per share. Each CVR will entitle its holder to deferred cash payments of $10.00 per CVR payable upon the U.S. Food and Drug Administration (FDA) approval of Bylvay in the Biliary Atresia indication at the latest by 31 December 2027, allowing for a potential increase in the number of patients in the BOLD study. The investigation concerns whether the Albireo Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Ipsen is paying too little for the Company.
Additional information can be found at https://www.brodskysmith.com/cases/albireo-nasdaq-albo/.
Duck Creek Technologies (Nasdaq - DCT)
Under the terms of the agreement, Duck Creek will be acquired by Vista Equity Partners (“Vista”). Duck Creek stockholders will receive $19.00 per share in an all-cash transaction valued at approximately $2.6 billion. The investigation concerns whether the Duck Creek Board breached its fiduciary duties to shareholders by failing to conduct a fair process, and whether Vista is paying too little for the Company.
Additional information can be found at https://www.brodskysmith.com/cases/duck-creek-technologies-nasdaq-dct/.
Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.
